NO320334B1 - Materialblanding av fast agarose-overtrukket agaroseinneholdende eller agarose-kollagenperle inneholdende celler som produserer et diffunderbart biologisk produkt, anvendelser derav, fremgangsmater for fremstilling derav, kondisjonert medium fremstilt ved hjelp av materialblandingen, samt fremgangsmate for a bestemme om en materialblanding er anvendelig i a undertrykke proliferasjon av cancerceller. - Google Patents

Materialblanding av fast agarose-overtrukket agaroseinneholdende eller agarose-kollagenperle inneholdende celler som produserer et diffunderbart biologisk produkt, anvendelser derav, fremgangsmater for fremstilling derav, kondisjonert medium fremstilt ved hjelp av materialblandingen, samt fremgangsmate for a bestemme om en materialblanding er anvendelig i a undertrykke proliferasjon av cancerceller. Download PDF

Info

Publication number: NO320334B1
Authority: NO; Norway
Prior art keywords: cancer cells; bead; cells; agarose; enclosed
Prior art date: 1996-04-03

Application number

NO19984627A

Other languages

English (en)

Norwegian (no)

Other versions

NO984627L (no

NO984627D0 (no

Inventor

Albert L Rubin

Kanti Jain

Shirin Asina

Barry Smith

Kurt Stenzel

Original Assignee

Rogosin Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-03

Filing date

1998-10-02

Publication date

2005-11-21

1996-11-07 Priority claimed from US08/745,063 external-priority patent/US5888497A/en

1998-10-02 Application filed by Rogosin Inst filed Critical Rogosin Inst

1998-10-02 Publication of NO984627D0 publication Critical patent/NO984627D0/no

1998-11-30 Publication of NO984627L publication Critical patent/NO984627L/no

2005-11-21 Publication of NO320334B1 publication Critical patent/NO320334B1/no

Links

239000011324 bead Substances 0.000 title claims abstract description 174
229920000936 Agarose Polymers 0.000 title claims abstract description 93
239000007787 solid Substances 0.000 title claims abstract description 51
239000003636 conditioned culture medium Substances 0.000 title claims abstract description 44
229920001436 collagen Polymers 0.000 title claims abstract description 29
206010028980 Neoplasm Diseases 0.000 title claims description 160
201000011510 cancer Diseases 0.000 title claims description 145
238000000034 method Methods 0.000 title claims description 60
239000000203 mixture Substances 0.000 title claims description 57
230000035755 proliferation Effects 0.000 title claims description 34
238000002360 preparation method Methods 0.000 title abstract description 4
108010035532 Collagen Proteins 0.000 claims abstract description 16
102000008186 Collagen Human genes 0.000 claims abstract description 16
239000003814 drug Substances 0.000 claims abstract description 4
210000004027 cell Anatomy 0.000 claims description 299
239000000463 material Substances 0.000 claims description 40
239000001963 growth medium Substances 0.000 claims description 26
210000004881 tumor cell Anatomy 0.000 claims description 21
230000004663 cell proliferation Effects 0.000 claims description 20
238000004519 manufacturing process Methods 0.000 claims description 14
230000009702 cancer cell proliferation Effects 0.000 claims description 11
230000012010 growth Effects 0.000 claims description 11
230000002401 inhibitory effect Effects 0.000 claims description 9
208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
206010038389 Renal cancer Diseases 0.000 claims description 8
238000012258 culturing Methods 0.000 claims description 8
201000010982 kidney cancer Diseases 0.000 claims description 8
206010006187 Breast cancer Diseases 0.000 claims description 7
239000011248 coating agent Substances 0.000 claims description 7
238000000576 coating method Methods 0.000 claims description 7
230000009467 reduction Effects 0.000 claims description 5
238000001816 cooling Methods 0.000 claims description 4
230000010261 cell growth Effects 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
238000007710 freezing Methods 0.000 claims description 2
230000008014 freezing Effects 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
230000000379 polymerizing effect Effects 0.000 claims description 2
238000011084 recovery Methods 0.000 claims description 2
208000026310 Breast neoplasm Diseases 0.000 claims 5
201000009030 Carcinoma Diseases 0.000 claims 3
230000001575 pathological effect Effects 0.000 claims 3
210000002919 epithelial cell Anatomy 0.000 claims 2
208000006332 Choriocarcinoma Diseases 0.000 claims 1
206010060862 Prostate cancer Diseases 0.000 claims 1
208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
230000002159 abnormal effect Effects 0.000 claims 1
239000002609 medium Substances 0.000 abstract description 21
241000699670 Mus sp. Species 0.000 description 36
239000000047 product Substances 0.000 description 20
238000002474 experimental method Methods 0.000 description 16
239000000243 solution Substances 0.000 description 14
241000699666 Mus <mouse, genus> Species 0.000 description 13
210000002955 secretory cell Anatomy 0.000 description 10
238000005538 encapsulation Methods 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
238000011534 incubation Methods 0.000 description 7
210000004153 islets of langerhan Anatomy 0.000 description 7
238000002054 transplantation Methods 0.000 description 7
206010012601 diabetes mellitus Diseases 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000011160 research Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
239000007943 implant Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
108010045569 atelocollagen Proteins 0.000 description 4
239000012620 biological material Substances 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
230000028993 immune response Effects 0.000 description 4
238000002513 implantation Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000007758 minimum essential medium Substances 0.000 description 4
239000011049 pearl Substances 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
206010024264 Lethargy Diseases 0.000 description 3
229940072056 alginate Drugs 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
239000003124 biologic agent Substances 0.000 description 3
230000000740 bleeding effect Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000003094 microcapsule Substances 0.000 description 3
239000002480 mineral oil Substances 0.000 description 3
235000010446 mineral oil Nutrition 0.000 description 3
230000004044 response Effects 0.000 description 3
206010000060 Abdominal distension Diseases 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
229920006362 Teflon® Polymers 0.000 description 2
210000000683 abdominal cavity Anatomy 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
239000003519 biomedical and dental material Substances 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000001610 euglycemic effect Effects 0.000 description 2
239000000835 fiber Substances 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000012510 hollow fiber Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
238000011835 investigation Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000011325 microbead Substances 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
230000001228 trophic effect Effects 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
206010003497 Asphyxia Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241001315286 Damon Species 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
108700021154 Metallothionein 3 Proteins 0.000 description 1
102100028708 Metallothionein-3 Human genes 0.000 description 1
102100034256 Mucin-1 Human genes 0.000 description 1
108010008707 Mucin-1 Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
229920006243 acrylic copolymer Polymers 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000000560 biocompatible material Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000003890 endocrine cell Anatomy 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000003292 glue Substances 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000008384 membrane barrier Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
238000010606 normalization Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
230000000580 secretagogue effect Effects 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
230000005851 tumor immunogenicity Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
230000035899 viability Effects 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Cell Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Dispersion Chemistry (AREA)
Urology & Nephrology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Materials For Medical Uses (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicinal Preparation (AREA)

NO19984627A 1996-04-03 1998-10-02 Materialblanding av fast agarose-overtrukket agaroseinneholdende eller agarose-kollagenperle inneholdende celler som produserer et diffunderbart biologisk produkt, anvendelser derav, fremgangsmater for fremstilling derav, kondisjonert medium fremstilt ved hjelp av materialblandingen, samt fremgangsmate for a bestemme om en materialblanding er anvendelig i a undertrykke proliferasjon av cancerceller. NO320334B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US62559596A	1996-04-03	1996-04-03
US08/745,063 US5888497A (en)	1996-04-03	1996-11-07	Agarose coated agarose beads containing cancer cells that produce material which suppresses cancer cell proliferation
PCT/US1997/004548 WO1997036495A1 (en)	1996-04-03	1997-03-21	Implantable agarose-collagen beads containing cells which produce a diffusible biological product, and uses thereof

Publications (3)

Publication Number	Publication Date
NO984627D0 NO984627D0 (no)	1998-10-02
NO984627L NO984627L (no)	1998-11-30
NO320334B1 true NO320334B1 (no)	2005-11-21

Family

ID=27089961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19984627A NO320334B1 (no)	1996-04-03	1998-10-02	Materialblanding av fast agarose-overtrukket agaroseinneholdende eller agarose-kollagenperle inneholdende celler som produserer et diffunderbart biologisk produkt, anvendelser derav, fremgangsmater for fremstilling derav, kondisjonert medium fremstilt ved hjelp av materialblandingen, samt fremgangsmate for a bestemme om en materialblanding er anvendelig i a undertrykke proliferasjon av cancerceller.

Country Status (15)

Country	Link
EP (2)	EP0914043B1 (de)
JP (2)	JP3765039B2 (de)
CN (2)	CN1296477C (de)
AT (2)	ATE374034T1 (de)
AU (1)	AU722109C (de)
CA (1)	CA2250880C (de)
DE (2)	DE69725317T2 (de)
DK (2)	DK0914043T3 (de)
ES (2)	ES2290390T3 (de)
FI (1)	FI120332B (de)
IL (1)	IL126442A0 (de)
NO (1)	NO320334B1 (de)
NZ (2)	NZ331960A (de)
PT (1)	PT914043E (de)
WO (1)	WO1997036495A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7297331B2 (en)	1996-04-03	2007-11-20	The Rogosin Institute	Beads containing restricted cancer cells producing material suppressing cancer cell proliferation
US6303151B1 (en) *	1996-04-03	2001-10-16	The Rogosin Institute	Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
US6224912B1 (en) *	1996-04-03	2001-05-01	The Rogo Institute	Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
NO983911D0 (no)	1998-08-26	1998-08-26	Norsk Hydro As	Alginatkapsler til bruk ved behandling av hjernesvulst
AU2003264652B2 (en) *	1998-11-09	2006-09-14	The Rogosin Institute	Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof
US8257715B1 (en)	2004-08-26	2012-09-04	University Of Notre Dame	Tissue vaccines and uses thereof
US8802113B2 (en)	2005-10-27	2014-08-12	University Of Notre Dame	Extracellular matrix cancer vaccine adjuvant
US9308252B2 (en)	2005-10-27	2016-04-12	Cook Biotech, Inc.	Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8778360B2 (en) *	2005-10-27	2014-07-15	University Of Notre Dame	Extracellular matrix cancer vaccine adjuvant
US8778362B2 (en)	2005-10-27	2014-07-15	University Of Notre Dame	Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
US9283266B2 (en)	2008-02-28	2016-03-15	University Of Notre Dame	Metastasis inhibition preparations and methods
US8846059B2 (en)	2009-12-08	2014-09-30	University Of Notre Dame	Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
NZ624195A (en) *	2012-01-31	2015-07-31	Rogosin Inst	Improved method for manufacture of macrobeads
US12038432B2 (en)	2018-02-02	2024-07-16	Wake Forest University Health Sciences	Organoids related to immunotherapy and methods of preparing and using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE441009B (sv) *	1982-03-08	1985-09-02	Kjell Nilsson	Sett att immobilisera levande biomaterial i perlformiga polymerer
US4798786A (en) *	1982-05-06	1989-01-17	Stolle Research And Development Corporation	Living cells encapsulated in crosslinked protein
CA1196862A (en) *	1983-06-01	1985-11-19	Connaught Laboratories Limited	Microencapsulation of living tissue and cells
US4663286A (en) *	1984-02-13	1987-05-05	Damon Biotech, Inc.	Encapsulation of materials
SE8604684L (sv) *	1986-11-03	1988-05-04	Excorim Kommanditbolag	Sett att belegga fasta partiklar med en hydrofil gel samt genom settet belagda partiklar
JP2691557B2 (ja) *	1988-04-15	1997-12-17	興研株式会社	人の悪性腫瘍細胞増殖抑制剤
US5053332A (en) *	1989-07-24	1991-10-01	Cook Richard B	Agarose beads, preferably incorporating biological materials
US5241051A (en) *	1992-04-24	1993-08-31	Research Development Foundation	Oncoinhibin
DK1666585T3 (da) *	1994-01-13	2009-01-12	Rogosin Inst	Makroindkapslede sekretoriske celler
US5651980A (en) *	1994-04-15	1997-07-29	Biohybrid Technologies, Inc.	Methods of use of uncoated gel particles

1997
- 1997-03-21 AT AT03018701T patent/ATE374034T1/de active
- 1997-03-21 EP EP97915180A patent/EP0914043B1/de not_active Expired - Lifetime
- 1997-03-21 CA CA002250880A patent/CA2250880C/en not_active Expired - Fee Related
- 1997-03-21 CN CNB031522718A patent/CN1296477C/zh not_active Expired - Fee Related
- 1997-03-21 ES ES03018701T patent/ES2290390T3/es not_active Expired - Lifetime
- 1997-03-21 DK DK97915180T patent/DK0914043T3/da active
- 1997-03-21 WO PCT/US1997/004548 patent/WO1997036495A1/en not_active Ceased
- 1997-03-21 DE DE69725317T patent/DE69725317T2/de not_active Expired - Lifetime
- 1997-03-21 JP JP53532197A patent/JP3765039B2/ja not_active Expired - Fee Related
- 1997-03-21 CN CN97193544A patent/CN1119080C/zh not_active Expired - Fee Related
- 1997-03-21 AT AT97915180T patent/ATE250858T1/de active
- 1997-03-21 AU AU22188/97A patent/AU722109C/en not_active Ceased
- 1997-03-21 DK DK03018701T patent/DK1382346T3/da active
- 1997-03-21 IL IL12644297A patent/IL126442A0/xx unknown
- 1997-03-21 ES ES97915180T patent/ES2206696T3/es not_active Expired - Lifetime
- 1997-03-21 PT PT97915180T patent/PT914043E/pt unknown
- 1997-03-21 NZ NZ331960A patent/NZ331960A/en not_active IP Right Cessation
- 1997-03-21 EP EP03018701A patent/EP1382346B1/de not_active Expired - Lifetime
- 1997-03-21 DE DE69738170T patent/DE69738170T2/de not_active Expired - Lifetime
1998
- 1998-09-11 FI FI981957A patent/FI120332B/fi not_active IP Right Cessation
- 1998-10-02 NO NO19984627A patent/NO320334B1/no not_active IP Right Cessation
1999
- 1999-08-06 NZ NZ33710999A patent/NZ337109A/xx not_active IP Right Cessation
2004
- 2004-12-28 JP JP2004378949A patent/JP4480152B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
WO1997036495A1 (en)	1997-10-09
CN1119080C (zh)	2003-08-27
DK0914043T3 (da)	2004-02-09
ATE250858T1 (de)	2003-10-15
CN1495253A (zh)	2004-05-12
CA2250880A1 (en)	1997-10-09
JP3765039B2 (ja)	2006-04-12
FI981957A0 (fi)	1998-09-11
EP1382346A1 (de)	2004-01-21
IL126442A0 (en)	1999-08-17
FI981957L (fi)	1998-12-02
CN1296477C (zh)	2007-01-24
NZ331960A (en)	1999-10-28
EP1382346B1 (de)	2007-09-26
HK1066026A1 (en)	2005-03-11
FI120332B (fi)	2009-09-30
DE69738170T2 (de)	2008-01-24
AU722109C (en)	2001-07-19
ATE374034T1 (de)	2007-10-15
ES2206696T3 (es)	2004-05-16
NZ337109A (en)	2004-12-24
AU2218897A (en)	1997-10-22
NO984627L (no)	1998-11-30
CA2250880C (en)	2008-01-15
DK1382346T3 (da)	2008-01-28
EP0914043B1 (de)	2003-10-01
JP2005104987A (ja)	2005-04-21
PT914043E (pt)	2004-02-27
HK1019037A1 (en)	2000-01-21
NO984627D0 (no)	1998-10-02
EP0914043A1 (de)	1999-05-12
JP2001503380A (ja)	2001-03-13
JP4480152B2 (ja)	2010-06-16
CN1215309A (zh)	1999-04-28
AU722109B2 (en)	2000-07-20
EP0914043A4 (de)	2001-08-29
DE69738170D1 (de)	2007-11-08
DE69725317D1 (de)	2003-11-06
DE69725317T2 (de)	2004-07-29
ES2290390T3 (es)	2008-02-16

Legal Events

Date	Code	Title	Description
2016-10-24	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US6818230B2 (en)	2004-11-16	Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
US5888497A (en)	1999-03-30	Agarose coated agarose beads containing cancer cells that produce material which suppresses cancer cell proliferation
US20070110774A1 (en)	2007-05-17	Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof
NO320334B1 (no)	2005-11-21	Materialblanding av fast agarose-overtrukket agaroseinneholdende eller agarose-kollagenperle inneholdende celler som produserer et diffunderbart biologisk produkt, anvendelser derav, fremgangsmater for fremstilling derav, kondisjonert medium fremstilt ved hjelp av materialblandingen, samt fremgangsmate for a bestemme om en materialblanding er anvendelig i a undertrykke proliferasjon av cancerceller.
JP2005104987A5 (de)	2006-01-26
RU2173986C2 (ru)	2001-09-27	Имплантируемые агарозно-коллагеновые шарики, содержащие клетки, которые продуцируют способный к диффузии биологический продукт, и их применение
KR100477296B1 (ko)	2005-05-16	확산성의생물학적산물생산세포를함유하는이식가능한아가로오스-콜라겐비드,및그의용도
HK1019037B (en)	2004-05-14	Implantable agarose-collagen beads containing cells which produce a diffusible biological product, and uses thereof
HK1088928A (en)	2006-11-17	Conditioned medium containing a tumor cell proliferation suppressive factor and process of making the same
HK1066026B (en)	2007-05-25	Conditioned medium containing a tumor cell proliferation suppressive factor and process of making the same
MXPA01002927A (en)	2002-03-05	Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof